The “4th FCF Life Science Venture Capital Report” addresses recent financing trends in the Life Science industry, investigating subsector activity, deal characteristics, cross-border and investor engagements in Europe and the US.
Key insights were:
- Europe has continued its upward trend of life science venture financing in Europe, with UK recording the most transactions and highest volumes in the last 5 years
- Oncology was the most sought indication in 2019, with BioNTech leading the TOP 10 deals in Europe
- The biggest 2019 vintage funds were raised from British and French investors, pushing European venture capital fundraising volumes to the highest level in the last 5 years
- Cross-border investors tend to play a more important role, especially in later stage rounds, with the US being the most important cross-border investor in Europe
To access the full report, please click here.